Evidence map›Paper›PMID 35348740›Full record

ReviewJournal of travel medicine2022

The antimicrobial resistance travel tool, an interactive evidence-based educational tool to limit antimicrobial resistance spread.

Fabiana Arieti, Alessia Savoldi, Nithya Babu Rejendran, Marcella Sibani, Maela Tebon, Maria Diletta Pezzani, Anna Gorska, Teresa M Wozniak, Evelina Tacconelli

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of travel medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Fabiana ArietiDivision of Infectious Diseases, Department of Diagnostics and Public Health, University of Verona, Verona 37134, Italy.
Alessia SavoldiDivision of Infectious Diseases, Department of Diagnostics and Public Health, University of Verona, Verona 37134, Italy.
Nithya Babu RejendranDivision of Infectious Diseases, Department of Internal Medicine I, German Center for Infection Research, University of Tübingen, Tübingen 72074, Germany.
Marcella SibaniDivision of Infectious Diseases, Department of Diagnostics and Public Health, University of Verona, Verona 37134, Italy.
Maela TebonDivision of Infectious Diseases, Department of Diagnostics and Public Health, University of Verona, Verona 37134, Italy.
Maria Diletta PezzaniDivision of Infectious Diseases, Department of Medicine, Verona University Hospital, Verona 37134, Italy.
Anna GorskaDivision of Infectious Diseases, Department of Diagnostics and Public Health, University of Verona, Verona 37134, Italy.
Teresa M WozniakMenzies School of Health Research, Charles Darwin University, Darwin 8100, Northern Territory, Australia.
Evelina TacconelliDivision of Infectious Diseases, Department of Diagnostics and Public Health, University of Verona, Verona 37134, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInternational travel has been recognized as a risk factor contributing to the spread of antimicrobial resistance (AMR). However, tools focused on AMR in the context of international travel and designed to guide decision-making are limited. We aimed at developing an evidence-based educational tool targeting both healthcare professionals (HCPs) and international travellers to help prevent the spread of AMR.

methodsA literature review on 12 antimicrobial-resistant bacteria (ARB) listed as critical and high tiers in the WHO Pathogen Priority List covering four key areas was carried out: AMR surveillance data; epidemiological studies reporting ARB prevalence data on carriage in returning travellers; guidance documents reporting indications on screening for ARB in returning travellers and recommendations for ARB prevention for the public. The evidence, catalogued at country-level, provided the content for a series of visualizations that allow assessment of the risk of AMR acquisition through travel.

resultsUp to January 2021, the database includes data on: (i) AMR surveillance for 2.018.241 isolates from 86 countries; (ii) ARB prevalence of carriage from 11.679 international travellers and (iii) 15 guidance documents published by major public health agencies. The evidence allowed the development of a consultation scheme for the evaluation of risk factors, prevalence of carriage, proportion and recommendations for screening of AMR. For the public, pre-travel practical measures to minimize the risk of transmission were framed.

conclusionsThis easy-to-use, annually updated, freely accessible AMR travel tool (https://epi-net.eu/travel-tool/overview/), is the first of its kind to be developed. For HCPs, it can provide a valuable resource for teaching and a repository that facilitates a stepwise assessment of the risk of AMR spread and strengthen implementation of optimized infection control measures. Similarly, for travellers, the tool has the potential to raise awareness of AMR and outlines preventive measures that reduce the risk of AMR acquisition and spread.

Indexed as

Anti-Bacterial AgentsDrug Resistance, BacterialAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsHumansTravelAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAnti-Bacterial AgentsAMRInternational travellingSurveillance

Identifiers

PMID35348740
PMCPMC9282094

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.